Bain Capital Life Sciences Opportunities III, LP 13D and 13G filings for Kyverna Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 5:20 pm Purchase |
2024-02-07 | 13G | Kyverna Therapeutics, Inc. KYTX |
Bain Capital Life Sciences Opportunities III, LP | 3,163,868 7.400% |
3,163,868 (New Position) |
Filing |